Q
Quince Therapeutics
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases
About Quince Therapeutics
Quince Therapeutics, Inc. operates as a late-stage biopharmaceutical company, strategically focused on developing and commercializing therapeutics for rare and debilitating diseases. Initially incorporated as Cortexyme, Inc. in 2012 by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric, the company rebranded to Quince Therapeutics in August 2022.
A pivotal moment in the company's recent history was the acquisition of EryDel S.p.A., a privately-held Italian biotech firm, in October 2023. This transaction was structured as a stock-for-stock exchange with no upfront cash, but includes potential downstream milestone payments of up to $485 million. Through this acquisition, Quince obtained EryDel's lead asset, now named eDSP (formerly EryDex), and its proprietary drug delivery technology. The company's business model is centered on advancing its clinical pipeline, funded by cash reserves and strategic partnerships, rather than revenue from product sales. As a clinical-stage entity, its financial health is characterized by significant investment in research and development.
The company is led by CEO and CMO Dr. Dirk Thye, a seasoned executive with extensive experience in biotechnology, company creation, and drug development, having led multiple companies to successful exits and FDA approvals. His background spans infectious diseases, oncology, inflammation, and CRISPR gene editing. Dr. Thye previously served as CEO of Novosteo, which Quince acquired in May 2022.
Quince's core technology is the Autologous Intracellular Drug Encapsulation (AIDE) platform, a drug/device combination that encapsulates pharmaceuticals within a patient's own red blood cells. This method is designed to optimize drug delivery by improving tolerability, enhancing biodistribution, prolonging circulating half-life, and reducing immunogenicity. The primary application of the AIDE platform is eDSP, which encapsulates dexamethasone sodium phosphate (DSP). This formulation aims to deliver the anti-inflammatory benefits of corticosteroids for treating Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease, while minimizing the severe side effects associated with long-term steroid use. There are currently no approved treatments for A-T. The company completed enrollment for its pivotal Phase 3 NEAT clinical trial for eDSP in July 2025 and anticipates reporting topline results in the first quarter of 2026.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2019
News
Open roles
Quince Therapeutics in the South San Francisco ecosystem
The Quince Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- PVPfizer Ventures
Series A21 investors entered at this stage
Takeda
Takeda Ventures
Pfizer
Dolby Family Ventures
Sequoia
Verily
Cercano Management- SFSmallcap World Fund
Janus Henderson Investors
Columbia Threadneedle Investments
Cormorant Asset Management
Balyasny Asset Management
LifeSci Venture Partners
Affinity Asset Advisors- CCCoastlands Capital
Foresite Capital
Eventide Asset Management
Perceptive Advisors
Logos Capital
Woodline Partners
SilverArc Capital
Series B and later1 investor entered at this stage
Breakout Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quince Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quince Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


